Share This Page
Drug Price Trends for NDC 10135-0583
✉ Email this page to a colleague
Average Pharmacy Cost for 10135-0583
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 10135-0583
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 10135-0583
Introduction
The pharmaceutical landscape for NDC (National Drug Code) 10135-0583 revolves around a specific therapeutic product, with implications spanning clinical demand, manufacturing, regulatory pathways, and pricing strategies. As a crucial element in healthcare procurement and investment decision-making, understanding market dynamics and forward-looking price trends is essential for stakeholders including investors, healthcare providers, and pharmaceutical companies.
This analysis synthesizes current market conditions, competitive landscape, regulatory environment, and potential price trajectories to offer comprehensive insights into the drug’s market standing and future valuation.
Product Overview
NDC 10135-0583 corresponds to Temozolomide Capsules (commonly marketed under the brand name Temodar), a chemotherapeutic agent primarily indicated for the treatment of glioblastoma multiforme and certain astrocytomas. As an oral alkylating agent, Temozolomide has become a cornerstone in neuro-oncology, particularly following FDA approval for specific cancer types.
The drug’s mechanism involves DNA methylation, leading to apoptosis of tumor cells. Its oral formulation offers advantages in outpatient management, improving patient compliance.
Market Landscape and Demand Drivers
Clinical Demand
Glioblastoma multiforme (GBM) remains a highly aggressive, rapidly progressing brain tumor with limited treatment options. Temozolomide’s pivotal role, reinforced by landmark trials such as the Stupp protocol, sustains high demand. Market adoption is further driven by:
- FDA approvals expanding indications, including recurrent gliomas.
- Growing prevalence of brain cancers, projected to increase globally, with estimates indicating approximately 3.2 cases per 100,000 annually in the US[1].
- Favorable oral administration route, reducing hospitalization costs and improving quality of life.
Competitive Landscape
Temozolomide faces competition from other chemotherapeutic agents and emerging targeted therapies. Key competitors include generic formulations, which are increasingly prevalent following patent expirations, and emerging investigational drugs aimed at novel pathways.
Major manufacturers and generic producers compete on price and availability. Notably, the presence of multiple generic versions has historically driven price reductions in the US and globally.
Manufacturing and Supply Chain Factors
The production of Temozolomide involves complex chemical synthesis, with reliance on precursor availability and manufacturing capacity. Supply chain disruptions can impact pricing and availability. Recent trends indicate increased manufacturing capacity among generic manufacturers, leading to a saturated market.
Regulatory Environment
The regulatory landscape influences market entry and pricing. Patent expirations, especially for the branded version (originally by Schering-Plough, now Merck), open pathways for generic competition, which exerts downward pressure on prices.
Recent regulatory data show that multiple generic versions have received FDA approval, further intensifying price competition[2].
Furthermore, payer reimbursement policies and formulary preferences significantly impact market penetration and pricing strategies. Payers tend to favor generics due to cost savings, leading to a prioritization of lower-cost formulations.
Current Pricing Trends
Brand vs. Generic Pricing
Historically, the branded version of Temozolomide commanded higher prices, often exceeding $10 per capsule at launch. Following patent expiry, generic versions entered the market at a steep discount, reducing average capsule prices by 30-70% over the past decade[3].
Price Trends in Key Markets
- United States: The average wholesale price (AWP) for branded Temozolomide stood at approximately $24 per capsule in 2017, declining to around $8-$12 for generics by 2022.
- International Markets: Prices vary significantly, with developed countries witnessing a similar trend of generic price reductions. Emerging markets benefit from lower baseline prices but may face challenges related to regulatory approval and supply stability.
Reimbursement and Payer Strategies
Payer pressure and formulary eliminations support generic uptake, maintaining a competitive price environment. Manufacturer strategies include volume discounts and value-based agreements to sustain profitability amid price erosion.
Price Projections: 2023-2028
Short-Term (Next 1-2 Years)
- Stability and Slight Decline: Given the already saturated generic market, prices are expected to stabilize or decline marginally, around 5-10%. Market saturation limits further sharp reductions.
- Influence of Biosimilar Development: Although biosimilars are more relevant for biologics, any advances in targeted chemotherapies for brain tumors could affect Temozolomide’s pricing structure indirectly.
Mid to Long-Term (3-5 Years)
- Impact of Patent and Market Dynamics: With no new patents scheduled, generic competition is likely to persist, maintaining current low-price levels.
- Emergence of Novel Alternatives: Advances in targeted therapies, immunotherapies, or combination regimens could erode Temozolomide demand, pressuring prices downward.
- Regulatory Changes: Potential incentives for biosimilar or innovative drug development could alter market share and pricing.
Projected Price Range
Based on current trends and market forces, capsule prices are forecasted to remain within $8 to $12 per capsule for generic versions into 2028. The branded version, if still marketed, might retain premiums up to $20 per capsule, but lost market share to generics is expected to continue suppressing branded prices.
Market Valuation and Investment Outlook
Current global sales for Temozolomide approximate $600-$800 million annually, predominantly driven by the US and European markets. The price stability and volume of prescriptions suggest moderate growth prospects, primarily influenced by expanding indications and new cancer treatment modalities.
Investors should monitor patent status, regulatory approvals for new indications, and emerging therapies that could impact demand. The commoditization trend in generics suggests limited upside in pricing but stable revenue streams if volume is maintained.
Key Risks and Opportunities
Risks
- Market Saturation: Excess supply from multiple generic manufacturers reduces margins.
- Emerging Therapies: Novel targeted treatments or immunotherapies for glioblastoma could diminish Temozolomide’s market share.
- Regulatory Changes: Price controls or reimbursement reforms may further impact profitability.
Opportunities
- Expansion into New Indications: Investigating off-label or expanded indications can open additional market channels.
- Formulation Improvements: Developing combination therapies or sustained-release formulations could command premium pricing.
- Global Market Penetration: Growth in emerging markets offers revenue expansion, albeit at lower price points.
Key Takeaways
- Market Dynamics: Temozolomide’s established role in neuro-oncology ensures steady demand, but widespread generic competition maintains low pricing.
- Price Trajectory: Expect marginal declines or stabilization in prices over the next five years, with generic capsule prices likely remaining within $8-$12.
- Investment Implication: Given market saturation, revenue growth is primarily volume-based; strategic positioning in emerging markets may enhance profitability.
- Competitive Landscape: Ongoing patent expirations reinforce price competition; innovation in drug delivery or indication expansion could create value.
- Regulatory and Market Risks: Continued price pressures, evolving treatment standards, and market entry barriers necessitate vigilant monitoring.
Conclusion
NDC 10135-0583, associated with Temozolomide Capsules, remains a vital therapeutic agent in brain cancer management. Market forces predict sustained low-price levels driven by generic competition, with limited potential for significant price increases. Stakeholders should focus on volume optimization, geographic expansion, and innovation to maintain viable profit margins amidst a mature market landscape.
FAQs
1. What are the primary factors influencing the price of Temozolomide?
The main factors include patent expiration, generic competition, manufacturing costs, regulatory approvals, and payer reimbursement policies.
2. How has the entry of generics affected Temozolomide pricing?
Generic entry has significantly decreased capsule prices, often by over 50%, fostering a highly competitive market environment.
3. Are there upcoming regulatory changes that could impact the market?
While no major patent protections are currently active, regulatory incentives or new indications could modify demand or pricing strategies.
4. What are the prospects for branded Temozolomide in the current market?
The branded version is likely to face ongoing erosion of market share due to low-cost generics, limiting its pricing power.
5. Can future innovations disrupt the current market dynamics?
Yes, advances in targeted therapies or immunotherapies could reduce reliance on Temozolomide, impacting demand and pricing substantially.
References
[1] American Cancer Society. "Brain and Central Nervous System Cancers." 2022.
[2] U.S. Food and Drug Administration. "Approved Drug Products with Therapeutic Equivalence Evaluations." 2023.
[3] IQVIA. "National Prescription Audit." 2022.
More… ↓
